Remission of Extensive Merkel Cell Carcinoma After Electrochemotherapy

Curatolo, P.; Mancini, Monica; Clerico, Rita; Ruggiero, A; Frascione, Pasquale; Marco, Pierangelo Di; Frasca, Mirko; Calvieri, Stefano

doi:10.1001/archdermatol.2009.25

Cited by 16 publications

(12 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Efficacy of electrochemotherapy has been reported to be independent of the treated tumour types [14,15,42,49,82,92]. Similarly, in the current review, electrochemotherapy was found to be effective for basal cell carcinoma [2,21,50,78,93], malignant melanoma [2,5,12,13,17,21,23,36,40,73,74,79,92,[94][95][96][97], cutaneous lesions of breast cancer [2,63,64,80], squamous cell carcinoma [2,21,96,[98][99][100], Kaposi's sarcoma [55][56][57], Merkel cell carcinoma [41,60,61,96,101], and other tumours. The efficacy of this method is presented in more detail in table 2.…”

Section: Clinical Responses To Electrochemotherapy For Malignant Cutasupporting

confidence: 60%

“…It can therefore be used at lower doses than those needed for classic chemotherapies [7,13,31]. In previous studies, electrochemotherapy with bleomycin was found to be effective for primary and metastatic malignant melanoma [2,5,17,20,30,[36][37][38][39][40][41][42][43][44][45][46][47][48][49], primary and metastatic basal cell carcinoma [2,21,38,44,[50][51][52], primary and metastatic squamous cell carcinoma [44,47,49,53], Kaposi's sarcoma [41,43,49,[54][55][56][57][58][59], Merkel cell carcinoma [41,60,61], cutaneous primary and metastatic lesions of breast cancer [49,[62][63]…”

Section: Choice Of Chemotherapeutic Agent For Electroporationmentioning

confidence: 99%

See 1 more Smart Citation

Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis

Jafari¹,

Lak²,

Gazdhar³

et al. 2018

European Journal of Dermatology

View full text Add to dashboard Cite

Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis Electrochemotherapy is becoming a promising technique for the management of malignancies of skin and non-skin origin. The current review aims to clarify current knowledge on administration of electrochemotherapy for the treatment of various skin tumours. A systematic literature search was performed, up to the end of 2016, on studies in which the application of electrochemotherapy for management of primary and metastatic cutaneous malignant tumours was assessed. Having selected appropriate studies, pooled estimates of mean objective (complete) responses, with 95% confidence intervals (CIs), were calculated to assess treatment efficacy. Finally, the main emerging themes from the papers were discussed in more detail. From 465 records identified through database searching, a total of 128 studies were screened, of which 70 were included for review. After a pooled analysis, the estimate for mean objective response following electrochemotherapy was 84.02% (95% CI: 80.08-87.61). Furthermore, the pooled estimate of objective treatment response of evaluated studies was 83.91% (95% CI: 79.15-88.17%) for bleomycin and 80.82% (95% CI: 66.00-92.36%) for cisplatin. Electrochemotherapy is a feasible, inexpensive, fast and easy technique to perform local treatment, regardless of tumour type, with a low level of adverse effects and patient discomfort. This method can be applied alone for patients with primary cutaneous lesions, or local or locoregional metastases, or as an additional treatment modality in patients with distant metastases.

show abstract

Section: Clinical Responses To Electrochemotherapy For Malignant Cutasupporting

confidence: 60%

Section: Choice Of Chemotherapeutic Agent For Electroporationmentioning

confidence: 99%

Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis

Jafari¹,

Lak²,

Gazdhar³

et al. 2018

European Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Preclinical developments before the use of electrochemotherapy first in human patients, and subsequent research, helped define its mechanism of action, the most effective treatment parameters, both electrical and pharmacological, and the most suitable operating procedures for safe and reproducible treatments. Electrochemotherapy has been repeatedly and independently shown to be highly effective in providing local tumor control and palliation of symptomatic lesions located in cutaneous or subcutaneous tissues regardless of their histological origin, while maintaining a very low toxicity profile and high patient acceptance [40][41][42][43][44][45][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65].…”

Section: Resultsmentioning

confidence: 99%

“…Electrochemotherapy has been successfully used in the treatment of skin tumors other than melanoma, such as Kaposi's sarcomas [56][57][58], metastatic basal cell carcinoma with squamous cell differentiation [59], and Merkel cell carcinoma [60].…”

Section: Eletcrochemotherapy In the Treatment Of Malignant Melanomamentioning

confidence: 99%

Electrochemotherapy for primary skin cancer and skin metastasis related to other malignancies

Reinhold

2011

Anti-Cancer Drugs

View full text Add to dashboard Cite

Electrochemotherapy is an effective local tumor ablation modality in the treatment of solid cancers. Its use combines the administration of nonpermeable or poorly permeable highly intrinsic cytotoxic drugs with the application of short and intense electric pulses to the tumors to facilitate the drug delivery into the cancer cells. After several preclinical and clinical studies using different and nonhomogenous protocols, the results of the multicenter European Standard Operating Procedure of Electrochemotherapy (ESOPE) project provided clinical procedures for a standardized, efficient, and safe electric pulse and drug administration protocol for the local treatment of any type of skin tumor nodules. Additional studies using the the multicenter European Standard Operating Procedure of Electrochemotherapy standard operating procedures confirmed the overall clinical results obtained. Currently, the tumors most frequently treated with ECT are melanoma and breast cancer metastasis, but also head and neck cancer, primary tumors of the skin, and Kaposi sarcoma. This review is intended as an update on the therapy and as an indication of possible future developments.

show abstract

“…Positive treatment results with BCC [11,118,122,[192][193][194][195][196][197][198][199][200] and SCC [122,172,187,[201][202][203] have been reported in several case series ( Table 7 ), while clinical experience in Merkel cell carcinoma [204][205][206] , sebaceous carcinoma [207] , and keratoacanthoma is still patchy [11,92,118,122,123,127,177,196,197,208,209] . ECT can be advantageous in patients with multifocal BCC (eg, in Gorlin-Goltz syndrome or Xeroderma Pigmentosum) to reduce the morbidity associated with repetitive surgical excisions [109,197] , and several creditable reports are available [109,47,192,193,199,210] .…”

Section: Nonmelanoma Skin Cancermentioning

confidence: 99%